Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies
Summary
GBI Research’s new report, “Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies”, provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research finds that early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.
The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).
Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.
Scope
Summary
GBI Research’s new report, “Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies”, provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research finds that early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.
The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).
Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.
Scope
- Coverage of pipeline molecules in various discovery and pre-clinical phases of drug development along with pipeline analysis of the leading therapeutic segments, including Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders
- Analysis of the above mentioned disorders market in the leading geographies of the world, which are the US, the UK, Germany, France, Italy, Spain and Japan
- Key drivers and barriers that have a significant impact on the market
- Competitive benchmarking of leading companies. The key companies studied in this report are Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffmann-La Roche Ltd, Mirna Therapeutics, Inc. and Aphios Corporation
- Key M&A activities and licensing agreements that have taken place between 2005 and 2010 in the global Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders markets
- Align your product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding the key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – INTRODUCTION
2.1 GBI Research Report Guidance
3 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA - OVERVIEW
3.1 Drug Discovery and Development
3.1.1 Drug Development-Stages
3.2 Early Stage Drug Discovery Studies- An overview
3.3 Early Stage Drug Discovery Design and Planning
3.3.1 Early Stage Drug Discovery – Strategic Planning
3.3.2 Key Considerations During Early Stage Drug Discovery
4 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA - TECHNOLOGY LANDSCAPE
4.1 Current System
4.1.1 Overview
4.1.2 Key Technologies
4.1.3 In-vitro ADMET Screening Models
4.1.4 In vivo ADMET Screening Models
4.1.5 In silico ADMET Screening models
4.2 Trends in Technology Models
4.2.1 Recent Technology Developments
5 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA - DRUG DISCOVERY AND DEVELOPMENT – A CHALLENGE TO PHARMACEUTICAL COMPANIES
5.1 Drug Discovery & Development Process
5.1.1 Drug Discovery Process
6 DRUG DISCOVERY AND PRECLINICAL MOLECULES IN THERAPEUTIC SEGMENTS
6.1 Central Nervous System Disorders
6.1.1 Alzheimer’s disease
6.1.2 Parkinson’s disease
6.1.3 Multiple Sclerosis
6.1.4 Schizophrenia
6.2 Metabolic Disorders
6.2.1 Diabetes
6.2.2 Obesity
6.3 Immunological Disorders
6.3.1 Rheumatoid Arthritis
6.3.2 Crohn’s Disease
6.3.3 Systemic Lupus Erythematosus (SLE)
6.3.4 Allergy
6.4 Infections
6.4.1 HIV/AIDS
6.4.2 Hepatitis A, B, C
6.5 Cardiovascular Diseases
6.5.1 Hypertension
6.5.2 Dyslipidemia
6.5.3 Pulmonary Arterial Hypertension (PAH)
6.5.4 Myocardial Infarction
6.6 Oncology
6.6.1 Bladder Cancer
6.6.2 Lung Cancer
6.6.3 Non-Small Cell Lung Cancer (NSLC)
6.6.4 Breast Cancer
6.6.5 Colon Cancer
6.6.6 Melanoma
6.6.7 Ovarian Cancer
6.6.8 Prostate Cancer
7 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – TOP FIVE PHARMACEUTICAL PLAYERS IN EARLY STAGE DRUG DISCOVERY
7.1 Introduction
7.2 Hanall Pharmaceutical
7.2.1 Company Overview
7.2.2 Pipeline
7.3 Patrys Limited
7.3.1 Company Overview
7.3.2 Pipeline
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.2 Pipeline
7.5 Mirna Therapeutics
7.5.1 Company Overview
7.5.2 Pipeline
7.6 Aphios Corporation
7.6.1 Company Overview
7.6.2 Pipeline
8 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – STRATEGIC CONSOLIDATIONS
8.1 R&D Licensing Agreements
8.1.1 Deals by Indication
8.1.2 Deals by Geography
8.1.3 Deal Summaries by Therapeutic Class
9 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – APPENDIX
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
LIST OF TABLES
Table 1: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Alzheimer’s Disease, December 2010
Table 2: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Parkinson’s Disease, December 2010
Table 3: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Multiple Sclerosis, December 2010
Table 4: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Schizophrenia, December 2010
Table 5: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Diabetes, December 2010
Table 6: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Obesity, December 2010
Table 7: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Rheumatoid Arthritis Therapeutics, December 2010
Table 8: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Crohn’s Disease, December 2010
Table 9: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in SLE, December 2010
Table 10: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Allergy, December 2010
Table 11: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Patent Expiries of Major Marketed Drugs in HIV/AIDS, December 2010
Table 12: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in HIV/AIDS, December 2010
Table 13: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Hepatitis Therapeutics, December 2010
Table 14: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Hypertension Therapeutics, December 2010
Table 15: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics, December 2010
Table 16: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in PAH Therapeutics, December 2010
Table 17: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in PAH Therapeutics (%), December 2010
Table 18: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Myocardial Infarction Therapeutics, December 2010
Table 19: Drug Discovery and Preclinical Molecules by Therapy Area, Bladder Cancer Therapeutics, Prevalence by Country, 2009
Table 20: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics, December 2010
Table 21: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics (%), December 2010
Table 22: Drug Discovery and Preclinical Molecules by Therapy Area, Lung Cancer Categorized by Disease Stage, December 2010
Table 23: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Lung Cancer Therapeutics, December 2010
Table 24: Drug Discovery and Preclinical Molecules by Therapy Area, Global, NSCLC Treatment by Stage of the Disease, December 2010
Table 25: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in NSLC Therapeutics, December 2010
Table 26: Drug Discovery and Preclinical Molecules by Therapy Area, Breast Cancer Stage Classification, December 2010
Table 27: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Breast Cancer, December 2010
Table 28: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Global, Staging of Colon Cancer, December 2010
Table 29: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Colon Cancer Therapeutics, December 2010
Table 30: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of Melanoma, December 2010
Table 31: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Melanoma, December 2010
Table 32: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of Ovarian Cancer, December 2010
Table 33: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics, December 2010
Table 34: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of Prostate Cancer, December 2010
Table 35: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics, December 2010
Table 36: Drug Discovery and Preclinical Molecules by Therapy Area, Hanall Pharmaceutical – Pipeline Products, December 2010
Table 37: Drug Discovery and Preclinical Molecules by Therapy Area, Patrys Limited – Pipeline Products, December 2010
Table 38: Drug Discovery and Preclinical Molecules by Therapy Area, F. Hoffmann-La Roche Ltd. – Pipeline Products, December 2010
Table 39: Drug Discovery and Preclinical Molecules by Therapy Area, Mirna Therapeutics, Inc. – Pipeline Products, December 2010
Table 40: Drug Discovery and Preclinical Molecules by Therapy Area, Aphios Corporation, Inc. – Pipeline Products, December 2010
Table 41: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Metabolic Disorders (%), 2005–2010
Table 42: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Immunological Disorders (%), 2005–2010
Table 43: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Cardiovascular Disorders (%), 2005–2010
Table 44: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Infections, 2005–2010
Table 45: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Oncology, 2005–2010
Table 46: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Central Nervous System Disorders, 2005–2010
LIST OF FIGURES
Figure 1: Drug Discovery and Preclinical Molecules by Therapy Area, Series of Research Activities Leading to Drug Discovery, December 2010
Figure 2: Drug Discovery and Preclinical Molecules by Therapy Area, Stages of Drug Development, December 2010
Figure 3: Drug Discovery and Preclinical Molecules by Therapy Area, Preclinical ADMET Studies, December 2010
Figure 4: Drug Discovery and Preclinical Molecules by Therapy Area, Recent Technological Developments in Early Stage Development, December 2010
Figure 5: Drug Discovery and Preclinical Molecules by Therapy Area by Therapy, December 2010
Figure 6: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Different Therapeutic Segments December 2010
Figure 7: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline in Alzheimer’s Disease (%), December 2010
Figure 8: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Alzheimer’s Disease (%), December 2010
Figure 9: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Parkinson’s Disease (%), December 2010
Figure 10: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Parkinson’s Disease (%), December 2010
Figure 11: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Multiple Sclerosis (%), December 2010
Figure 12: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Multiple Sclerosis (%), December 2010
Figure 13: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Schizophrenia (%), December 2010
Figure 14: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Schizophrenia (%), December 2010
Figure 15: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline in Diabetes (%), December 2010
Figure 16: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Diabetes (%), December 2010
Figure 17: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Obesity (%), December 2010
Figure 18: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Obesity (%), December 2010
Figure 19: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Rheumatoid Arthritis Therapeutics (%), December 2010
Figure 20: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Rheumatoid Arthritis (%), December 2010
Figure 21: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Crohn’s Disease (%), December 2010
Figure 22: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Crohn’s Disease (%), December 2010
Figure 23: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in SLE (%), December 2010
Figure 24: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in SLE (%), December 2010
Figure 25: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Allergy(%), December 2010
Figure 26: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Allergy (%), December 2010
Figure 27: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in HIV/AIDS Therapeutics (%), December 2010
Figure 28: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in HIV/AIDS (%), December 2010
Figure 29: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Hepatitis Therapeutics (%), December 2010
Figure 30: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Hepatitis Therapeutics (%), December 2010
Figure 31: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline by Phase in Hypertension Therapeutics (%), December 2010
Figure 32: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Mechanism of Action in Hypertension Therapeutics (%), December 2010
Figure 33: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics (%), December 2010
Figure 34: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Dyslipidemia Therapeutics (%), December 2010
Figure 35: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in PAH (%), December 2010
Figure 36: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Phase in Myocardial Infarction (%), December 2010
Figure 37: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Myocardial Infarction (%), December 2010
Figure 38: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Bladder Cancer Therapeutics (%), December 2010
Figure 39: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Lung Cancer Therapeutics (%), December 2010
Figure 40: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Lung Cancer Therapeutics (%), December 2010
Figure 41: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in NSLC Therapeutics (%), December 2010
Figure 42: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Mechanism of Action in NSLC Therapeutics (%), December 2010
Figure 43: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Breast Cancer Therapeutics (%), December 2010
Figure 44: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Breast Cancer Thereapeutics (%), December 2010
Figure 45: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Colon Cancer Therapeutics (%), December 2010
Figure 46: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Colon Cancer Therapeutics (%), December 2010
Figure 47: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Phase in Melanoma Therapeutics (%), December 2010
Figure 48: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Melanoma Therapeutics (%), December 2010
Figure 49:Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics (%), December 2010
Figure 50: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics(%), December 2010
Figure 51: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics (%), December 2010
Figure 52: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics (%), December 2010
Figure 53: Drug Discovery and Preclinical Molecules by Therapy Area, Top Five Pharmaceutical Players in Early Stage Drug Develpment, December 2010
Figure 54: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Indication (%), 2005–2010
Figure 55: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Geography (%), 2005–2010
COMPANIES MENTIONED
Hanall Pharmaceutical
Patrys Limited
F. Hoffmann-La Roche Ltd.
Mirna Therapeutics
Aphios Corporation
1.1 List of Tables
1.2 List of Figures
2 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – INTRODUCTION
2.1 GBI Research Report Guidance
3 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA - OVERVIEW
3.1 Drug Discovery and Development
3.1.1 Drug Development-Stages
3.2 Early Stage Drug Discovery Studies- An overview
3.3 Early Stage Drug Discovery Design and Planning
3.3.1 Early Stage Drug Discovery – Strategic Planning
3.3.2 Key Considerations During Early Stage Drug Discovery
4 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA - TECHNOLOGY LANDSCAPE
4.1 Current System
4.1.1 Overview
4.1.2 Key Technologies
4.1.3 In-vitro ADMET Screening Models
4.1.4 In vivo ADMET Screening Models
4.1.5 In silico ADMET Screening models
4.2 Trends in Technology Models
4.2.1 Recent Technology Developments
5 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA - DRUG DISCOVERY AND DEVELOPMENT – A CHALLENGE TO PHARMACEUTICAL COMPANIES
5.1 Drug Discovery & Development Process
5.1.1 Drug Discovery Process
6 DRUG DISCOVERY AND PRECLINICAL MOLECULES IN THERAPEUTIC SEGMENTS
6.1 Central Nervous System Disorders
6.1.1 Alzheimer’s disease
6.1.2 Parkinson’s disease
6.1.3 Multiple Sclerosis
6.1.4 Schizophrenia
6.2 Metabolic Disorders
6.2.1 Diabetes
6.2.2 Obesity
6.3 Immunological Disorders
6.3.1 Rheumatoid Arthritis
6.3.2 Crohn’s Disease
6.3.3 Systemic Lupus Erythematosus (SLE)
6.3.4 Allergy
6.4 Infections
6.4.1 HIV/AIDS
6.4.2 Hepatitis A, B, C
6.5 Cardiovascular Diseases
6.5.1 Hypertension
6.5.2 Dyslipidemia
6.5.3 Pulmonary Arterial Hypertension (PAH)
6.5.4 Myocardial Infarction
6.6 Oncology
6.6.1 Bladder Cancer
6.6.2 Lung Cancer
6.6.3 Non-Small Cell Lung Cancer (NSLC)
6.6.4 Breast Cancer
6.6.5 Colon Cancer
6.6.6 Melanoma
6.6.7 Ovarian Cancer
6.6.8 Prostate Cancer
7 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – TOP FIVE PHARMACEUTICAL PLAYERS IN EARLY STAGE DRUG DISCOVERY
7.1 Introduction
7.2 Hanall Pharmaceutical
7.2.1 Company Overview
7.2.2 Pipeline
7.3 Patrys Limited
7.3.1 Company Overview
7.3.2 Pipeline
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.2 Pipeline
7.5 Mirna Therapeutics
7.5.1 Company Overview
7.5.2 Pipeline
7.6 Aphios Corporation
7.6.1 Company Overview
7.6.2 Pipeline
8 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – STRATEGIC CONSOLIDATIONS
8.1 R&D Licensing Agreements
8.1.1 Deals by Indication
8.1.2 Deals by Geography
8.1.3 Deal Summaries by Therapeutic Class
9 DRUG DISCOVERY AND PRECLINICAL MOLECULES BY THERAPY AREA – APPENDIX
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
LIST OF TABLES
Table 1: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Alzheimer’s Disease, December 2010
Table 2: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Parkinson’s Disease, December 2010
Table 3: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Multiple Sclerosis, December 2010
Table 4: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Schizophrenia, December 2010
Table 5: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Diabetes, December 2010
Table 6: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Obesity, December 2010
Table 7: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Rheumatoid Arthritis Therapeutics, December 2010
Table 8: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Crohn’s Disease, December 2010
Table 9: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in SLE, December 2010
Table 10: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Allergy, December 2010
Table 11: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Patent Expiries of Major Marketed Drugs in HIV/AIDS, December 2010
Table 12: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in HIV/AIDS, December 2010
Table 13: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Hepatitis Therapeutics, December 2010
Table 14: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Hypertension Therapeutics, December 2010
Table 15: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics, December 2010
Table 16: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in PAH Therapeutics, December 2010
Table 17: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in PAH Therapeutics (%), December 2010
Table 18: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Myocardial Infarction Therapeutics, December 2010
Table 19: Drug Discovery and Preclinical Molecules by Therapy Area, Bladder Cancer Therapeutics, Prevalence by Country, 2009
Table 20: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics, December 2010
Table 21: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics (%), December 2010
Table 22: Drug Discovery and Preclinical Molecules by Therapy Area, Lung Cancer Categorized by Disease Stage, December 2010
Table 23: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Lung Cancer Therapeutics, December 2010
Table 24: Drug Discovery and Preclinical Molecules by Therapy Area, Global, NSCLC Treatment by Stage of the Disease, December 2010
Table 25: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in NSLC Therapeutics, December 2010
Table 26: Drug Discovery and Preclinical Molecules by Therapy Area, Breast Cancer Stage Classification, December 2010
Table 27: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Breast Cancer, December 2010
Table 28: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Global, Staging of Colon Cancer, December 2010
Table 29: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Colon Cancer Therapeutics, December 2010
Table 30: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of Melanoma, December 2010
Table 31: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Melanoma, December 2010
Table 32: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of Ovarian Cancer, December 2010
Table 33: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics, December 2010
Table 34: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Staging of Prostate Cancer, December 2010
Table 35: Drug Discovery and Preclinical Molecules by Therapy Area, Global, Early Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics, December 2010
Table 36: Drug Discovery and Preclinical Molecules by Therapy Area, Hanall Pharmaceutical – Pipeline Products, December 2010
Table 37: Drug Discovery and Preclinical Molecules by Therapy Area, Patrys Limited – Pipeline Products, December 2010
Table 38: Drug Discovery and Preclinical Molecules by Therapy Area, F. Hoffmann-La Roche Ltd. – Pipeline Products, December 2010
Table 39: Drug Discovery and Preclinical Molecules by Therapy Area, Mirna Therapeutics, Inc. – Pipeline Products, December 2010
Table 40: Drug Discovery and Preclinical Molecules by Therapy Area, Aphios Corporation, Inc. – Pipeline Products, December 2010
Table 41: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Metabolic Disorders (%), 2005–2010
Table 42: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Immunological Disorders (%), 2005–2010
Table 43: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Cardiovascular Disorders (%), 2005–2010
Table 44: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Infections, 2005–2010
Table 45: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Oncology, 2005–2010
Table 46: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Therapeutic Class, Central Nervous System Disorders, 2005–2010
LIST OF FIGURES
Figure 1: Drug Discovery and Preclinical Molecules by Therapy Area, Series of Research Activities Leading to Drug Discovery, December 2010
Figure 2: Drug Discovery and Preclinical Molecules by Therapy Area, Stages of Drug Development, December 2010
Figure 3: Drug Discovery and Preclinical Molecules by Therapy Area, Preclinical ADMET Studies, December 2010
Figure 4: Drug Discovery and Preclinical Molecules by Therapy Area, Recent Technological Developments in Early Stage Development, December 2010
Figure 5: Drug Discovery and Preclinical Molecules by Therapy Area by Therapy, December 2010
Figure 6: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Different Therapeutic Segments December 2010
Figure 7: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline in Alzheimer’s Disease (%), December 2010
Figure 8: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Alzheimer’s Disease (%), December 2010
Figure 9: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Parkinson’s Disease (%), December 2010
Figure 10: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Parkinson’s Disease (%), December 2010
Figure 11: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Multiple Sclerosis (%), December 2010
Figure 12: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Multiple Sclerosis (%), December 2010
Figure 13: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Schizophrenia (%), December 2010
Figure 14: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Schizophrenia (%), December 2010
Figure 15: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline in Diabetes (%), December 2010
Figure 16: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Diabetes (%), December 2010
Figure 17: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Obesity (%), December 2010
Figure 18: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Obesity (%), December 2010
Figure 19: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Rheumatoid Arthritis Therapeutics (%), December 2010
Figure 20: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Rheumatoid Arthritis (%), December 2010
Figure 21: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in Crohn’s Disease (%), December 2010
Figure 22: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Crohn’s Disease (%), December 2010
Figure 23: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in SLE (%), December 2010
Figure 24: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in SLE (%), December 2010
Figure 25: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Allergy(%), December 2010
Figure 26: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Allergy (%), December 2010
Figure 27: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline in HIV/AIDS Therapeutics (%), December 2010
Figure 28: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in HIV/AIDS (%), December 2010
Figure 29: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Hepatitis Therapeutics (%), December 2010
Figure 30: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Hepatitis Therapeutics (%), December 2010
Figure 31: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D pipeline by Phase in Hypertension Therapeutics (%), December 2010
Figure 32: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Mechanism of Action in Hypertension Therapeutics (%), December 2010
Figure 33: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics (%), December 2010
Figure 34: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Dyslipidemia Therapeutics (%), December 2010
Figure 35: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in PAH (%), December 2010
Figure 36: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Phase in Myocardial Infarction (%), December 2010
Figure 37: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Myocardial Infarction (%), December 2010
Figure 38: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Bladder Cancer Therapeutics (%), December 2010
Figure 39: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Lung Cancer Therapeutics (%), December 2010
Figure 40: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Lung Cancer Therapeutics (%), December 2010
Figure 41: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in NSLC Therapeutics (%), December 2010
Figure 42: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Mechanism of Action in NSLC Therapeutics (%), December 2010
Figure 43: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Breast Cancer Therapeutics (%), December 2010
Figure 44: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Breast Cancer Thereapeutics (%), December 2010
Figure 45: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Colon Cancer Therapeutics (%), December 2010
Figure 46: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Colon Cancer Therapeutics (%), December 2010
Figure 47: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Phase in Melanoma Therapeutics (%), December 2010
Figure 48: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Melanoma Therapeutics (%), December 2010
Figure 49:Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics (%), December 2010
Figure 50: Drug Discovery and Preclinical Molecules by Therapy Area , Early Stage R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics(%), December 2010
Figure 51: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics (%), December 2010
Figure 52: Drug Discovery and Preclinical Molecules by Therapy Area, Early Stage R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics (%), December 2010
Figure 53: Drug Discovery and Preclinical Molecules by Therapy Area, Top Five Pharmaceutical Players in Early Stage Drug Develpment, December 2010
Figure 54: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Indication (%), 2005–2010
Figure 55: Drug Discovery and Preclinical Molecules by Therapy Area, Major Licensing Agreements by Geography (%), 2005–2010
COMPANIES MENTIONED
Hanall Pharmaceutical
Patrys Limited
F. Hoffmann-La Roche Ltd.
Mirna Therapeutics
Aphios Corporation
